Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADICAL Trial: Neoadjuvant Radiotherapy + Dual Immunotherapy for Locally Advanced Rectal Cancer
NCT07596290Phase 3Not yet recruiting
- Sponsor
- Beijing Friendship Hospital
- Start
- Jul 2026
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of paromlimab, tuvonralimab in rectal cancer, sponsored by Beijing Friendship Hospital. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
paromlimabtuvonralimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07596290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07596290.